Divestment agreement expands decade-long collaboration between Sanofi and Cheplapharm, helps to hone Sanofi’s innovation focus.
Sanofi, through a new partnership, is divesting of 20 mature medicines and three of its global manufacturing sites to long-time collaborator European pharmaceutical company Cheplapharm.
While the two companies commenced their initial collaboration in 2014, the present partnership enables Sanofi to concentrate its efforts on innovation, meanwhile advancing certain established medicines through the development lifecycle.
More broadly, Sanofi and Cheplapharm explained “that innovative medicines and certain mature medicines have different needs and should benefit from operating models tailored to their specific manufacturing, regulatory and commercial requirements.”
Our multi-year journey to simplify our mature portfolio has enabled us to focus on innovation while ensuring mature medicines continue to reach patients who need them”
Thomas Grenier, Executive Vice President, General Medicines, Sanofi
Thomas Grenier, Executive Vice President, General Medicines, Sanofi, said: “Our multi-year journey to simplify our mature portfolio has enabled us to focus on innovation while ensuring mature medicines continue to reach patients who need them. Cheplapharm has been a trusted partner for more than a decade and this transaction significantly builds on its prior acquisitions from Sanofi’s mature medicines portfolio.”
The three manufacturing sites Sanofi plans to transfer to Cheplapharm are: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees) and Ploërmel in France (c.65 employees).
As part of the agreement, the mature medicines being divested by Sanofi include the small molecule thromboembolic disorder-indicated Lovenox/Clexane (enoxaparin), excluding the US. In return, Sanofi will receive a 26.4 percent equity stake in Cheplapharm.
Edeltraud Lafer and Sebastian Braun, Co-CEOs of Cheplapharm, added: “This partnership marks a major milestone for Cheplapharm. Through this project, we are incorporating products that complement our extensive portfolio, as well as the expertise and manufacturing capabilities required to produce a flagship product, Lovenox/Clexane.
“This represents a long-term pharmaceutical and industrial commitment: to invest in our sites and their expertise, to preserve rare skills, and to ensure the long-term availability of these treatments for patients. We are proud to pursue this ambition alongside Sanofi.”
The commercial transfer of Sanofi’s medicine portfolio and manufacturing sites is expected to be finalised by Q3 of 2027, subject to customary closing conditions.
Sanofi and Cheplapharm plan to share further financial details of the partnership at a later date.
No comments yet